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BACKGROUND: In renal cell carcinoma (RCC), the discovery of biomarkers for clinical use is a priority. This study aimed to identify and
validate diagnostic and prognostic serum markers using proteomic profiling.
METHODS: Pre-operative sera from 119 patients with clear cell RCC and 69 healthy controls was analysed by surface-enhanced laser
desorption/ionisation time-of-flight mass spectrometry with stringent in-house quality control and analysis routines. Following
identification of one prognostic peak as a fragment of serum amyloid A (SAA), total serum SAA and CRP were also determined by
immunoassay for further validation.
RESULTS: Several peptides were identified as having independent prognostic but not diagnostic significance on multivariable analysis.
One was subsequently identified as a 1525Da fragment of SAA (hazard ratio (HR)¼0.26, 95% CI 0.08–0.85, P¼0.026). This was
weakly negatively correlated with total SAA, which was also of independent prognostic significance (HR¼2.46, 95% CI 1.17–5.15,
P¼0.017). Both potentially strengthened prognostic models based solely on pre-operative variables.
CONCLUSIONS: This is the first description of the prognostic value of this peptide in RCC and demonstrates proof of principle of the
approach. The subsequent examination of SAA protein considerably extends previous studies, being the first study to focus solely on
pre-operative samples and describing potential clinical utility in pre-operative prognostic models.
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Renal cell carcinoma (RCC) is the most common cancer of the
kidney with the main histological subtype being conventional
(clear cell), which accounts for around 75% of cases (Rini et al,
2009) and commonly involves the VHL tumour suppressor gene
(Young et al, 2009). Approximately 60% of patients have clinically
localised disease at presentation, with the majority undergoing
curative nephrectomy. However, a third of these patients subse-
quently relapse with metastatic disease. Although several promis-
ing markers for RCC have been identified, none currently have
been validated and are in routine use (Eichelberg et al, 2009).
There is considerable interest in biomarker development generally,
both in the context of improving safety and in ‘personalised/
individualised’ medicine by facilitating earlier and more accurate
diagnosis, improving assessment of prognosis, detection of relapse
and prediction/monitoring of response (Eichelberg et al, 2009), all
of which have additional quality of life and economic benefits.
For RCC, diagnostic markers would be particularly valuable in
high-risk populations and in patients with unresectable disease,
possibly obviating the need for biopsies. Post-surgery, imaging is
the key follow-up modality although a multiplicity of regimens
have been proposed (Rouviere et al, 2006). Prognostic algorithms
generally combine TNM staging system with tumour grade, and
pathological or clinical factors (Galfano et al, 2008; Lane and
Kattan, 2008) but estimates of individual risk are relatively wide
and several parameters such as grading are subjective. More
recently, the possibility of using algorithms based on pre-operative
information has been explored with some success (Cindolo et al,
2003; Raj et al, 2008; Karakiewicz et al, 2009).
Various proteomics-based approaches are being applied
to biomarker discovery, each with their own strengths and
weaknesses (Issaq et al, 2007; Koomen et al, 2008). One of the
approaches that has attracted a lot of interest has been that
of surface-enhanced laser desorption/ionisation time-of-flight
mass spectrometry (SELDI-TOF-MS) for profiling samples.
Significant criticism has been applied to some earlier studies in
terms of experimental design, reproducibility and resolution
(Kiehntopf et al, 2007; Whelan et al, 2008), but much effort has
been made in addressing these issues. We have used SELDI
together with stringent in-house quality control (QC) (Cairns et al,
2009) and peak detection methods (Rogers et al, 2003) to
investigate whether we can find and validate new serum
markers of potential diagnostic or prognostic utility in RCC. On
the basis of the subsequent identification of a peak with significant
prognostic value as a fragment of serum amyloid A (SAA), we
have subsequently analysed total SAA as determined by
ELISA and compared the clinical prognostic value of both
total and C-terminal fragment of SAA pre-operatively, together
with CRP.
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Materials
All routine chemicals were from Sigma-Aldrich (Poole, UK) or
VWR Merck (Poole, UK). ProteinChips and calibrants were
purchased from Ciphergen Biosystems (now Bio-Rad, Herts, UK)
and sinapinic acid from Fluka (Fluka Chemicals Ltd., Buchs,
Switzerland). Bio-Suite CM 10mm CXC cation exchange HPLC
column 7.5 75mm was obtained from Waters (Herts, UK), Bond-
Elut 500mg C18-EWP solid-phase columns from Varian (Varian
Inc., Yarnton, Oxford, UK) and C18-zip tips were from Millipore
(Herts, UK). Milli-Q water (Millipore (UK) Ltd., Livingston, UK)
was used throughout. Monoclonal anti-human SAA (ab18713) was
purchased from Abcam (Cambridge, UK) and mouse IgG (MOPC-
21) from Sigma. Protein-G-coated Dynabeads (cat no: 100-03D)
were purchased from Invitrogen (Paisley, UK).
Patients and samples
Venous blood samples collected from 188 individuals in
2000–2003 (Table 1) comprising 69 healthy controls and 119
patients with clear cell RCC before nephrectomy (102 radical, 6
partial; 11 unknown) or other treatment were analysed. Four
Table 1 Demographic and clinical details of the patients and healthy
controls included in the study
Characteristic n (%)
Gender
Controls – male/female (n¼69) 40:29 (58.0:42.0)
RCC – male/female (n¼119) 61:58 (51.3:48.7)
Age at sampling (year)
Controls – median (range) 62 (28, 85)
Mean (s.d.) 59.0 (16.5)
RCC – median (range) 63 (28, 85)
Mean (s.d.) 61.1 (12.0)
p(Max tumour size; cm)
Median (range) 6 (2,16)
Mean (s.d.) 6.7 (3.4)
Missing 5 (4.2)
ct(Max tumour size; cm)
Median (range) 6 (1.7,16)
Mean (s.d.) 6.7 (3.4)
Missing 26 (21.9)
Fuhrman grade
1 5 (7.2)
2 35 (29.4)
3 43 (36.1)
4 35 (29.4)
Missing 1 (0.8)
pT stage
1a 25 (21.0)
1b 31 (26.1)
2 11 (9.2)
3a* 25 (21.0)
3b* 25 (21.0)
4 1 (0.8)
Missing 1 (0.8)
ctT stage
1a 30 (25.2)
1b 20 (16.8)
2 19 (16.0)
3 21 (17.6)
4 4 (3.4)
Missing 25 (21.0)
Table 1 (Continued)
Characteristic n (%)
N stage
0 92 (77.3)
X1 20 (16.8)
Missing 7 (5.9)
M stage
0 91 (76.5)
1 28 (23.5)
TNM stage
I 52 (43.7)
II 8 (6.7)
III** 29 (24.4)
IV 29 (24.4)
Missing 1 (0.8)
MVI/VI
No 44 (37.0)
Yes 75 (63.0)
Missing 0 (0)
Necrosis
No 73 (61.3)
Yes 38 (31.9)
Missing 8 (6.7)
Symptoms
Incidental/Asymptomatic 46 (38.7)
Local 38 (31.9)
Systemic 30 (25.2)
Missing 5 (4.2)
Follow-up (year)
Median (range) 2.52 (0.01, 5.88)
Mean (s.d.) 2.52 (1.38)
DFS
Events 20 (18.9)
Censored 49 (74.3)
Missing 5 (6.8)
CSS
Events 14 (14.7)
Censored 76 (80.0)
Missing 5 (5.3)
OS
Events 24 (25.3)
Censored 62 (65.3)
Missing 9 (9.5)
SAA fragment peak intensity
Median (range) 2.818 (0, 12.20)
Mean (s.d.) 3.71 (2.31)
SAA (mgl
 1)
Median (range) 6.30 (0.80, 1470.0)
Mean (s.d.) 148.10 (352.6)
CRP (mgl
 1)
Median (range) 7.15 (o5.00, 201.6)
Mean (s.d.) 27.33 (45.3)
Abbreviations: CRP¼C-reactive protein; CSS¼cancer-specific survival; DFS¼
disease-free survival; OS¼overall survival; RCC¼renal cell carcinoma; SAA¼serum
amyloid A.
aIncludes two and five patients, where pT¼‘at least’ 3a or 3b, respectively.
**Includes three patients for whom a minimum value only of III only could be
assigned for stage. For ctT, 3a and 3b are recorded as 3 only, as used in the
Karakiewicz et al (2009) model.
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spatients subsequently received adjuvant therapy. Samples were
obtained after informed consent and with the approval of the local
research ethics committee. Blood was collected into Z/serum clot
activator tubes (Greiner Bio-One Ltd, Stonehouse, UK) and
allowed to clot at room temperature for 30–60min before being
centrifuged at 1800g and 201C for 10min. Serum was aspirated,
aliquotted and stored at  801C until analysis.
This study was designed to follow the STARD and REMARK
(Bossuyt et al, 2003; McShane et al, 2005) guidelines for marker
identification and evaluation with the primary objective of
investigating differential expression in the SELDI profiles of RCC
and healthy controls and the planned subset analysis of
investigating prognostic significance of the profile. Using pilot
data it was shown that in order to detect a two-fold change in peak
intensity with a power of 95% at a significance level of a¼0.001
(to control false discovery rate) in 90% of the peaks in the serum
profile, 68 samples analysed in duplicate would be required in each
group. Additional samples were included in the RCC group as for
the prognostic investigation, it was calculated 137 samples would
be required at these significance levels and power to detect a
hazard ratio (HR) of 5 in a two-fold change in concentration, with
a probability of death of 27.5% in the expected follow-up period.
However, as only 119 samples were available, this power is
achieved in slightly fewer than 90% of the peaks.
For the diagnostic study, an initial set of 153 samples (51 normal
and 102 RCC) were analysed by SELDI over a period of 5 days. This
sample set was then split into a test and training set with similar
proportions of cases and controls. A further late test set of 49
samples (26 normal and 23 RCC, including 8 controls and 6 RCC
samples previously run in the initial set, to check the longer-term
reproducibility) was analysed by SELDI 6 months later. For the
prognostic analysis, data from all 119 RCC patients were used.
SELDI profiling
CM10 chips were prepared and samples applied as previously
described (Banks et al, 2005) but using 50mM HEPES/0.1% v/v
Triton X-100, pH 7.0 as the wash/dilution buffer. Chips were
analysed using a PBS-II SELDI-TOF (Ciphergen Biosystems) with
conditions and calibration described in Supplementary methods. All
serum samples were analysed in duplicate with each replicate being
randomised across days and chips. An experimental QC sample
(a serum pool prepared from 20 RCC and 20 normal serum samples)
was also included on each chip, assigned to spot A for the first chip,
spot B for the second and so on to ensure representative coverage of
each spot. Peak detection was carried out using in-house software as
previously described (Rogers et al, 2003). All samples and QC spectra
were subjected to a range of QC analyses using in-house software
(Cairns et al, 2009) and rerun as necessary.
Purification and identification of peak m/z 1528Da
In brief (full details in Supplementary Methods), serum diluted
with 25mM HEPES, pH 6.8 was injected onto a BioSuite CM 10mm,
CXC column. After washing, bound material was eluted with
increasing gradient to 1 M NaCl, with the presence of the 1528Da
peak in fractions being monitored by SELDI. Relevant fractions
were then concentrated, reduced, alkylated and desalted and
applied to a 384-well MALDI plate in a solution of 4-hydroxy-a-
cyano-cinnamic acid (CHCA) in 50% aqueous (v/v) acetonitrile/
0.1% (v/v) TFA. Positive-ion MALDI mass spectra were acquired
over a mass range of m/z 800–4000 using a Bruker Ultraflex III
(Bruker Daltonics, Bremen, Germany) in reflectron mode with
external calibration. Peaks in the relevant mass range were
manually selected for MS/MS fragmentation and MS/MS spectra
were baseline-subtracted and smoothed; monoisotopic peak
detection used a SNAP averaging algorithm with a minimum S/N
of 3. Bruker FlexAnalysis software was used to perform the spectral
processing and peak list generation. Tandem mass spectral data were
submitted to database searching against the NCBInr protein database
(2 July 2008) containing 194674 human sequences using Mascot
(Matrix Science Ltd., Matrix Science, Boston, MA, USA; version 2.1)
with search criteria including: Variable modifications – oxidation
(M); Peptide tolerance – 200p.p.m.; MS/MS tolerance – 0.8Da; and
Fixed modification – carbamidomethyl for all alkylated samples.
The identification of the 1525–1528Da peak was also confirmed
by immunoprecipitation of several RCC serum samples. In brief
(full details in Supplementary Methods), 20ml of serum was mixed
with protein G-Dynabeads coupled with either 2mg of mouse anti-
human SAA Ab or 2mg of mouse MOPC-21 antibody (negative
control). After washing, bound antigens were eluted with 20mlo f
100mM acetic acid before application to 0.6ml C18-zip-tips.
After washing with 0.1% (v/v) TFA bound species were eluted
onto gold chips using sinappinic acid or CHCA (for mass range
5–20 or 1–5kDa, respectively). Spectra were acquired using a PCS
4000 Enterprise Protein Chip Reader (Bio-Rad). Mass accuracy was
calibrated externally using the all-in-one peptide standard. Peaks
were detected after baseline subtraction and spectral calibration.
Immunoassay of SAA and CRP
O ft h eo r i g i n a lR C Cs e r u ms a m p l e s ,9 9 were available for subsequent
measurement of total SAA at the Supra-Regional Assay service in
Sheffield, UK, using rate nephelometry performed on Siemens BNII
with a Siemens (Siemens, Deerfield, IL, USA) kit based on a
polyclonal antibody. The CRP concentrations were also determined
using the Advia 1650 analyser (Bayer, Newbury, UK) in the Clinical
Biochemistry Department, St James’s University Hospital, Leeds, UK.
Normal range for both analytes was o10mgl
 1.
Data analysis
Diagnosis Peak detected profiles of RCC patients and healthy
controls were compared peak-by-peak using a linear mixed effects
(LMEs) model similarly to previously reported (Munro et al, 2006)
with a random effect for subject, and age and sex included as
covariates. The Random Forest classification algorithm (Liaw and
Weiner, 2002) selecting 10 random variables at each data split and
growing 50000 trees was used to assess the classification ability of
the profile, and identified differentially expressed peaks. Receiver
operating characteristic (ROC) curve analysis was undertaken to
quantify the diagnostic potential of the identified differentially
expressed peaks, with the area under the ROC curve (AUC)
estimated and a one-sided significance test performed of the null
hypothesis that AUC40.5, against the alternative that AUCp0.5
(i.e., no diagnostic ability). When examining multiple significance
tests from the LMEs for differential expression (and tests on HRs
for prognosis), significance levels of 0.1% (Po0.001) were used as
an ad hoc method of controlling the FDR.
Prognosis Peak detected profiles from RCC patients were
averaged across technical replicates and analysed (peak-by-peak)
with primary end points, including overall survival (OS), cancer-
specific survival (CSS) and disease-free survival (DFS; defined as
date of relapse or death from any cause in patients who were
disease-free after surgery), timed from the date of nephrectomy.
The Kaplan–Meier (KM) method, simple and multivariable Cox
proportional hazards regression and the likelihood ratio test (LRT)
were used to estimate and evaluate OS, CSS and DFS for the peaks,
other known prognostic variables and immunoassay-determined
total SAA and CRP. The distribution of the continuous measure-
ments was transformed to the log2 scale to simplify interpretation
of estimated HR, and when comparing peak and ELISA measure-
ments the concentrations were scaled by dividing by their standard
deviation to make the obtained HRs comparable. The relationship
between survival and each standard prognostic clinicopathological
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(Table 1) was assessed using HRs. In addition, given the interest in
using markers pre-operatively to assess prognosis, SAA and CRP
were considered together with the variables of age, gender,
symptom score, CT-derived size, T stage and presence or absence
of metastatic disease, as used in the pre-operative predictive
model of Karakiewicz et al (2009) to assess their independent
pre-operative predictive value. The assumption of proportional
hazards in the Cox regression was checked using the test of
Grambsch and Therneau for simple and multivariable analysis.
Analysis was undertaken using the R Environment for Statistical
Computing (R Development Core Team, Vienna) applying
functions in the nlme and survival libraries and in Stata 9.0
(College Station, TX, USA) using the lroc function.
RESULTS
Diagnosis
Over all spectra, a total of 383 different peaks were detected with a
median number of 92 in the healthy controls and 95 in the RCC
spectra. Three peaks (m/z 4802.1, 6675.9, 7341.1Da) were
significantly differently expressed between cases and controls.
Although these peaks were highly significant in terms of
differences in means, the distributions of the peak intensities
overlapped (Supplementary Figure 1). The intra-class correlation
coefficients are also quite small indicating only moderate
reproducibility (Supplementary Table 1). The limited value of
these peaks as diagnostic biomarkers was confirmed by ROC curve
analysis, in which each peak was found to have only limited
predictive ability with AUCE60%. The ability of the profile to
classify cases and controls was assessed using the Random
Forest. Examining the training set, first test set and blind test set
resulted in a high out-of-bag classification error (44%) and poor
classification in terms of sensitivity/specificity, that is in the training
set 73%/22%, in the test set 72%, 27% and in the blind validation
set 76%/31%, respectively. Considering that these results were
achieved in a comparison of healthy controls and RCC patients, a
subsequent comparison including benign disease controls in which
even poorer performance could be anticipated was not performed.
Prognosis
Details of the length of follow-up and number of events (CSS, DFS
and OS) are given in Table 1. CSS rates (95% CI) from nephrectomy
for all RCC patients were 87.5% (80.8–94.7%) for 1 year and 71.3%
(61.4–83.1%) for 3 years. DFS rates (95% CI) from nephrectomy for
all RCC patients were 91.0% (84.4–98.1%) for 1 year and 77.3%
(66.7–89.5%) for 3 years. Overall survival rates from nephrectomy
for all RCC patients were 86.5% (79.7–94.0%) for 1 year and 66.5%
(56.2–78.8%) for 3 years. Median CSS, DFS and OS were not
reached in this follow-up period. The characteristics of the cohort of
RCC patients were checked according to known prognostic factors
(Table 2) and, as expected, significant associations were identified
between CSS and several clinicopathological features including
grade, stage, microvascular invasion and necrosis.
Considering all RCC patients, no peaks were identified that were
significantly associated with DFS (Po0.001), but 12 peaks were
identified that were significantly associated with CSS (Po0.001 –
Supplementary Table 2). Six of these peaks (three of which are
shown in Figure 1) have independent prognostic value (Po0.001)
when fitting a multivariable model with age, sex, pT, M and
maximum tumour size included as covariates. One peak was
subsequently identified, namely, the peak of approximate m/z
1525–1528Da, the intensity of which was inversely related to
survival, as the C terminal 13 amino acid fragment of SAA
(P02735) with a predicted mass of 1525.8Da and Mascot score of 41,
indicating significant homology and common to both SAA-1 and
SAA-2 (Figure 2). The estimated HR for this peak in the univariate
analysis is shown in Table 2. It is encouraging that the HR in the
multivariable analysis (HR¼0.26, 95% CI 0.08–0.85, P¼0.026) is
similar to that in the single variable analysis and the 95% CIs
overlap to an extent also. As can be seen from examining the HR, P
columns in Table 2, no prognostic variables provided any evidence
of violating the proportional hazards assumptions in both the
simple and multivariable models. The identity of this peak was also
confirmed by immunoprecipitation (Figure 3) with several
additional peaks being specifically precipitated including the
11kDa cluster of three peaks previously identified (Tolson et al,
2004; Engwegen et al, 2007) as intact SAA (11.68kDa), des-R SAA
(11.5kDa) and des-RS SAA (11.4kDa). Peaks at 9.29 and 7.61kDa,
which may correspond to previously observed proteolytic break-
down products of SAA by cathepsin-B action (Rocken et al, 2005),
were also seen (data not shown).
The summary statistics for SAA as determined by immunoassay
are shown in Table 2, and show weak evidence of a negative
correlation of r¼ 0.16 (95% CI  0.35 to 0.04, P¼0.11) with the
intensity of the 1528Da SAA fragment. SAA was also strongly
positively correlated with CRP (r¼0.88, 95% CI 0.82–0.92,
Po10
 15) and showed evidence of an association (details in
Supplementary Results) with grade Po10
 5), pT (P¼0.002),
CT-determined T-stage (Po10
 3), TNM stage (P¼0.0003),
N stage (Po10
 3) and symptoms score (P¼0.007). In addition,
there was evidence of a positive correlation with tumour size
determined by CT (Pearson r¼0.416, Po10
 4) or pathology
(r¼0.368, Po10
 3). However, there was no evidence of an
association with M stage (P¼0.1611). There was no evidence of
significant association or correlation between these clinicopatho-
logical variables and the SAA peak fragment.
Figure 4 shows CSS for the SAA fragment of 1528Da, mature SAA
and CRP with increases in mature SAA and CRP being associated
with poorer survival. It is clear that the relationship between hazard
of death and concentration of SAA as measured by immunoassay is
in an opposing direction to the SAA fragment (Figure 4). This is
confirmed by examining the HR for SAA for univariate analysis in
Table 2 (HR¼3.77, 95% CI 2.35–6.05, Po10
 7). In fact, it is almost
exactly the reciprocal of the HR for the peak at 1528Da
(e
( log(3.77))¼0.27), a near perfect inverse relationship. The survival
function for CRP is very similar to that for SAA, which is possibly
not surprising considering their strong positive correlation.
The results of the multivariable analysis to test for independent
prognostic ability are shown in Table 2. The estimated HRs in the pre-
operative predictive model of Karakiewicz et al (2009) were contained
in the 95% CIs for HR for all, except one of the variables in Table 4
(local vs asymptomatic symptoms) indicating the transferability of this
model to our data. In addition, SAA is shown to have independent
prognostic ability (LRT, P¼0.017). The HR of the multivariable
analysis for SAA was similar, but reduced to that for the univariate
analysis, indicating that some of the relationship with survival time
explained by SAA is explained by the other variables in the model. The
SAA fragment was also an independent prognostic factor but when
CRP was added to the model, SAA or the SAA fragment were no
longer independent prognostic factors (SAA; LRT, P¼0.208), but
adding CRP to the model containing SAA and the other pre-operative
factors was independently prognostic (LRT, P¼0.004).
This analysis was similarly undertaken for OS and DFS
(Supplementary Tables 3 and 4). The SAA fragment and
immunoassay SAA measurement were found to be significantly
related with OS (Po0.05) on single variable analysis, and on
multivariable analysis there was some evidence of independent
prognostic ability for the SAA immunoassay measurement (LRT,
P¼0.080). However, these measurements were not found to be
significantly independently prognostic of DFS (LRT, P40.05),
although the HRs were similar to those found in CSS/OS. The CRP
was shown to be highly significantly related to OS (Po10
 7) and
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 3) in RCC. Similar analysis was undertaken for CSS,
DFS and OS considering non-cancer deaths, and no relationship
was found between the SAA fragment or total SAA or CRP
(P40.05), indicating the specific nature of the relationship of these
factors with prognosis and RCC.
DISCUSSION
This study demonstrates an important proof of principle of the
ability of a proteomic profiling approach to successfully detect a
potential prognostic serum biomarker, specifically a C-terminal
fragment of SAA, for renal cancer. Few such examples that exist in
the cancer literature currently and mainly address diagnosis. The
validity of the identified C-terminal fragment of SAA in serum as
being of independent prognostic significance in RCC with higher
levels being associated with better survival was further demon-
strated by its inverse correlation with intact SAA, as measured
by immunoassay and, importantly, almost perfectly inverse HRs
between the two. Critically, both this fragment and intact SAA have
been shown for the first time to provide additional information
Table 2 Univariate and multivariable prognostic modelling results for all RCC patients for CSS using Cox proportional hazards regression
Univariate analysis Multivariable analysis
Characteristic HR 95% CI PP H P HR 95% CI PP H P
SAA peak fragment 0.28 (0.12, 0.68) 0.005 0.229
SAA (mgl
 1) 3.77 (2.35, 6.05) o10
 7 0.490 2.46 (1.17, 5.15) 0.017 0.176
CRP (mgl
 1) 2.30 (1.75, 3.01) o10
 8 0.144
Age (year) 0.98 (0.95, 1.02) 0.330 0.157 0.95 (0.89, 1.01) 0.079 0.037
Sex
Male vs female 1.20 (0.52, 2.8) 0.670 0.346 1.13 (0.35, 3.66) 0.840 0.840
pT stage
T2 vs T1 4.96 (0.70, 35.2) 0.110 0.411
T3 vs T1 17.91 (4.10, 78.6) o10
 3 0.988
T4 vs T1 90.42 (7.41, 1103.3) o10
 3 0.714
0.695
ctT stage
T2 vs T1 2.69 (0.67, 10.8) 0.160 0.168 4.14 (0.36, 47.1) 0.250 0.071
T3/T4 vs T1 11.40 (3.65, 35.6) o10
 4 0.824 6.62 (0.81, 53.8) 0.077 0.214
0.286
N stage
N1 vs N0 15.40 (5.67, 42.1) o10
 7 0.498
N2 vs N0 16.80 (3.39, 83.6) o10
 3 0.937
0.744
M stage
M1 vs M0 15.90 (6.14, 41.2) o10
 7 0.967 5.81 (1.23, 27.4) 0.026 0.713
TNM stage
III vs I/II 16.80 (1.94, 145) 0.010 0.723
IV vs I/II 74.90 (9.84, 157) o10
 4 0.940
0.943
pMax. tumour diameter (cm) 1.21 (1.09, 1.34) o10
 3 0.294
ctMax. tumour diameter (cm) 1.22 (1.08, 1.36) o10
 3 0.393 1.03 (0.79, 1.33) 0.850 0.145
Fuhrman grade
G3 vs G1/G2 6.23 (0.72, 53.7) 0.096 0.921
G4 vs G1/G2 28.62 (3.65, 209.10) 0.001 0.862
0.998
MVI
Yes vs no 63.40 (8.39, 480) o10
 4 0.802
Necrosis
Yes vs no 6.50 (2.52, 16.8) o10
 3 0.498
Symptoms
Local vs asymptomatic 1.48 (0.30, 7.32) 0.630 0.829 0.16 (0.02, 1.56) 0.124 0.541
Systemic vs asymptomatic 11.84 (3.43, 40.75) o10
 4 0.791 1.36 (0.22, 8.50) 0.740 0.898
0.848 0.691
Abbreviations: CI¼confidence interval; CRP¼C-reactive protein; CSS¼cancer-specific survival; HR¼hazard ratio; RCC¼renal cell carcinoma; SAA¼serum amyloid A.
Multivariable results refer to the model considering immunoassay-determined SAA. PH P columns refer to the test for evidence of violation of the proportional hazards assumption.
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swhen used in combination with other clinical variables in pre-
operative prognostication.
There has been increasing interest in SAA, a major apolipopro-
tein of HDL, in cancer with the recognition that it is not just an
acute phase protein synthesised by the liver but is also produced
extrahepatically including by many cancers (Malle et al, 2009).
This includes renal cancer, particularly aggressive disease, on the
basis of microarray gene expression profiling studies and/or
quantitative RT-PCR (Liou et al., 2004; Kosari et al., 2005; Paret
et al, 2010). Epithelial cell expression of SAA-1 was subsequently
demonstrated by immunohistochemistry of clear cell RCC samples
as part of a TMA, correlating with a poor clinical outcome,
although only 15 of 87 cases were positive (Paret et al, 2010). As
such, it may therefore be both a tumour-derived factor in addition
to being a systemic reflection of the cytokines produced either
by the tumour or as a result of the host response and is present
in elevated concentrations in serum in many types of cancer
(Malle et al, 2009). Sustained chronic elevation of SAA, such as
that observed in some inflammatory diseases and cancers,
including renal cancer is thought to contribute to amyloidosis.
The ability of MALDI or SELDI-based fluid profiling to deliver
new potential biomarkers is still largely unproven (Findeisen and
Neumaier, 2009). The critical nature of sample handling (Banks
et al, 2005), the relatively poor mass resolution of some platforms
and lack of QC procedures have been problematic (Whelan et al,
2008; Findeisen and Neumaier, 2009). Although discrimination
between groups on the basis of profiles may be achieved,
the failure to demonstrate long-term robustness or to easily
identify peaks of interest has limited progress (Whelan et al, 2008).
This study has adopted stringent QC and analysis methods
together with consistent sample processing and has shown results
of potential utility, although again only one peak was able to be
identified despite extensive efforts. With MALDI-TOF-MS, the
peak was observed at an m/z 1525.81Da (1525–1528Da by SELDI-
TOF-MS) compared with a theoretical mass of 1525.73Da. The
theoretical pI is 9.01, which would be expected to bind to the chip
surface under the conditions used in this study, unlike SAA minus
the C terminal 13 amino acids with a pI of 6.57. Similarly, intact
SAA and the N-terminal truncated des-R and des-RS forms of
SAA-1 in RCC serum as previously described (Tolson et al, 2004;
Engwegen et al, 2007) were not detected by profiling as expected,
given their predicted pIs of 5.5–6.5 but were present in RCC serum
as revealed by our immunoprecipitation-MS experiments, along
with other fragments of SAA.
Functions of SAA relating to tumourigenesis (Malle et al, 2009)
include binding to extracellular matrix components with sub-
sequent potential modification of cell binding, enhancement of
plasminogen activation and stimulation of matrix metalloprotei-
nase (MMP) production, reported in several cell types including
renal cancer cell lines (Paret et al, 2010). Matrix metalloproteinases
can cleave SAA proteins (Stix et al, 2001), and C-terminal cleavage
of SAA by cathepsin-B (Rocken et al, 2005) and cathepsin-D has
been described (van der Hilst et al, 2009). There is no defined
motif for a specific protease cleavage site in SAA, which would
generate the 1528Da fragment described here. Numerous peptides
present in plasma or serum are largely generated from proteins
such as fibrinogen, thrombin and complement components
(Richter et al, 1999; Koomen et al, 2005; Zhou et al, 2006; Peng
et al, 2009). However, ‘disease-specific’ N- and C-terminal
exoprotease activities superimposed on these coagulation and
complement-based proteolytic events have been proposed to
generate disease-specific serum peptide signatures, including for
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sprostate, bladder and breast cancer (Villanueva et al, 2006). Such a
mechanism may account for the SAA fragment identified here.
Several SELDI profiling studies have detected elevated concentra-
tions of 11.7kDa mature form and peak clusters at 11.4–11.7kDa
lacking one or two amino acids in various cancers, including renal
cancer and particularly metastatic disease (Tolson et al, 2004;
Engwegen et al, 2007; Malle et al, 2009), with some subsequent
validation through immunoassay of SAA and demonstration of
high prognostic significance, for example, in melanoma (Findeisen
et al, 2009). These and other novel N-terminal truncated forms
and/or post-translationally modified forms of SAA1 and 2 have
been described in plasma samples from healthy controls and
patients with inflammatory diseases (Ducret et al, 1996; Kiernan
et al, 2003), although their significance is as yet unknown.
The possibility of serum SAA as measured by immunoassay
being of prognostic value in RCC has previously been examined in
two studies. The first involved 72 patients with RCC (47 clear cell),
where poor CSS was associated with higher SAA and SAA was an
independent prognostic factor on multivariate analysis, although
few parameters were examined (Kimura et al, 2001). A more recent
study involving 98 RCC patients (70 clear cell) found that SAA
concentration correlated significantly with T stage and grade.
Again only CSS was examined and SAA was found to be
independently significantly associated with survival, although only
T and M stage and grade were examined. (Ramankulov et al, 2008).
Interestingly, significantly higher concentrations of SAA were
found in patients with metastatic disease with the AUC for a ROC
analysis of metastatic vs non-metastatic disease of 0.86. However,
our study did not confirm this, with no evidence of metastatic
diagnostic potential being seen. The earlier study was slightly
complicated by the fact that almost half of the patients with
metastatic disease were sampled 1–76 months post-nephrectomy
when metastases were diagnosed, whereas in our study all samples
were obtained before any treatment. To what extent these assays
detect SAA fragments is not known but is very likely to be assay-
specific and dependent on antibody combinations and epitopes
recognised.
Our study clearly adds considerably to the literature being based
solely on patients with conventional clear cell RCC and all samples
being pre-treatment. In addition, OS, CSS and DFS were all
examined and with multiple variables for the models including
specifically a focus on pre-operative ones. The strong correlation
between CRP and SAA is to be expected, given their commonality
in terms of being induced by similar cytokines, although
kinetics in the acute situation differ with SAA being much more
sensitive and rapid in terms of increase and subsequent decline
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s(Banks et al, 1995; Malle and De Beer, 1996). Both CRP and SAA
were very highly independently statistically significant for prog-
nosis pre-operatively, although SAA lost this independence
when CRP was added, implying that CRP may provide additional
information. There is a body of evidence supporting CRP as an
independent prognostic marker in RCC (Ito et al, 2006;
Karakiewicz et al, 2007; Komai et al, 2007; Ramsey et al, 2008;
Iimura et al, 2009) and this may arise as a result of production by
the tumour cells themselves (Jabs et al, 2005). Clearly, although
correlated with many clinical variables, including T stage, nodal
status, grade, TNM stage and tumour size, both SAA and CRP
provide additional information of interest.
These findings warrant further study in larger patient groups
prospectively to determine conclusively the prognostic value of
SAA and CRP either alone or in combination with each other and
other prognostic variables available pre-operatively. Possible
utility in longitudinal monitoring should also be examined with
specificity being determined by repeated measurements to check
for transient rises due to episodes of acute inflammatory illnesses.
Clearly, measurement of SAA by immunoassay is superior to the
SAA fragment in terms of prognostic ability power, and therefore
developing an assay specifically for this fragment would not be
justified at present given the challenges involved, although it could
potentially provide additional information if a disease-specific
cleavage. Robust assays for SAA and CRP are already in place in
hospital clinical chemistry laboratories, providing relatively inexpen-
sive and objective measurement and facilitating future studies.
ACKNOWLEDGEMENTS
The financial support of Cancer Research UK is gratefully
acknowledged. We are also grateful to the patients for consenting
to participate, Annie Stanley for technical assistance, Jenny Barrett
for statistical discussions, Adam Dowd and Jerry Thomas of the
Technology facility at the University of York for protein
sequencing and the staff of the Urology, Pathology and Oncology
departments at St James’s University Hospital in Leeds.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
REFERENCES
Banks RE, Forbes MA, Storr M, Higginson J, Thompson D, Raynes J,
Illingworth JM, Perren TJ, Selby PJ, Whicher JT (1995) The acute
phase protein response in patients receiving subcutaneous IL-6.
Clin Exp Immunol 102: 217–223
Banks RE, Stanley AJ, Cairns DA, Barrett JH, Clarke P, Thompson D,
Selby PJ (2005) Influences of blood sample processing on low-molecular-
weight proteome identified by surface-enhanced laser desorption/
ionization mass spectrometry. Clin Chem 51(9): 1637–1649
SAA (1528 Da)
CRP (ELISA - mg l–1)
SAA (ELISA - mg l–1)
(Min,Q1)
(Q1,Q2)
(Q2,Q3)
(Q3,max)
S
u
r
v
i
v
a
l
1.0
0.8
0.6
0.4
0.2
0.0
S
u
r
v
i
v
a
l
1.0
0.8
0.6
0.4
0.2
0.0
S
u
r
v
i
v
a
l
1.0
0.8
0.6
0.4
0.2
0.0
Time (years)
012 3 4 56
Time (years)
012345 6
Time (years)
012 3 4 56
Figure 4 Plots of KM estimated survival functions for (A) peak intensity of SAA fragment (1528.9Da), (B) SAA concentration as determined by
immunoassay and, (C) CRP concentration, in each case split into quartiles. The legend in A applies to all panels but with the values for minimum, Q1, Q2,
Q3 and maximum being specific to each.
SAA and prognosis in renal cancer
SL Wood et al
109
British Journal of Cancer (2010) 103(1), 101–111 & 2010 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sBossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM,
Lijmer JG, Moher D, Rennie D, de Vet HC (2003) Towards complete and
accurate reporting of studies of diagnostic accuracy: the STARD
initiative. Standards for Reporting of Diagnostic Accuracy. Clin Chem
49(1): 1–6
Cairns DA, Perkins DN, Stanley AJ, Thompson D, Barrett JH, Selby PJ,
Banks RE (2009) Integrated multi-level quality control for proteomic
profiling studies using mass spectrometry. BMC Bioinformatics 9: 519
Cindolo L, De La Taille A, Messina G, Romis L, Abbou CC, Altieri V,
Rodriguez A, Patard JJ (2003) A preoperative clinical prognostic model
for non-metastatic renal cell carcinoma. BJU Int 92: 901–905
Ducret A, Bruun CF, Bures EJ, Marhaug G, Husby G, Aebersold R (1996)
Characterization of human serum amyloid A protein isoforms separated
by two-dimensional electrophoresis by liquid chromatography/
electrospray ionization tandem mass spectrometry. Electrophoresis 17:
866–876
Eichelberg C, Junker K, Ljungberg B, Moch H (2009) Diagnostic and
prognostic molecular markers for renal cell carcinoma: a critical
appraisal of the current state of research and clinical applicability.
Eur Urol 55: 851–863
Engwegen JY, Mehra N, Haanen JB, Bonfrer JM, Schellens JH, Voest EE,
Beijnen JH (2007) Validation of SELDI-TOF MS serum protein
profiles for renal cell carcinoma in new populations. Lab Invest 87(2):
161–172
Findeisen P, Neumaier M (2009) Mass spectrometry-based proteomics
profiling as diagnostic tool in oncology: current status and future
perspective. Clin Chem Lab Med 47: 666–684
Findeisen P, Zapatka M, Peccerella T, Matzk H, Neumaier M, Schadendorf D,
Ugurel S (2009) Serum amyloid A as a prognostic marker in melanoma
identified by proteomic profiling. JC l i nO n c o l13: 2199–2208
Galfano A, Novara G, Iafrate M, Cavalleri S, Martignoni G, Gardiman M,
D’Elia C, Patard JJ, Artibani W, Ficarra V (2008) Mathematical models
for prognostic prediction in patients with renal cell carcinoma. Urol Int
80: 113–123
Iimura Y, Saito K, Fujii Y, Kumagai J, Kawakami S, Komai Y, Yonese J,
Fukui I, Kihara K (2009) Development and external validation of a new
outcome prediction model for patients with clear cell renal cell
carcinoma treated with nephrectomy based on pre-operative serum
C-reactive protein and TNM classification: the TNM-C score. J Urol 181:
1004–1012
Issaq HJ, Xiao Z, Veenstra TD (2007) Serum and plasma proteomics. Chem
Rev 107: 3601–3620
Ito K, Asano T, Yoshii H, Satoh A, Sumitomo M, Hayakawa M (2006)
Impact of thrombocytosis and C-reactive protein elevation on the
prognosis for patients with renal cell carcinoma. Int J Urol 13: 1365–1370
Jabs WJ, Busse M, Kruger S, Jocham D, Steinhoff J, Doehn C (2005)
Expression of C-reactive protein by renal cell carcinomas and unaffected
surrounding renal tissue. Kidney Int 68: 2103–2110
Karakiewicz PI, Hutterer GC, Trinh QD, Jeldres C, Perrotte P, Gallina A,
Tostain J, Patard JJ (2007) C-reactive protein is an informative predictor
of renal cell carcinoma-specific mortality: a European study of 313
patients. Cancer 110: 1241–1247
Karakiewicz PI, Suardi N, Capitanio U, Jeldres C, Ficarra V, Cindolo L, De
La Taille A, Tostain J, Mulders PFA, Bensalah K, Artibani W, Salomon L,
Zigeuner R, Valeri A, Descotes J-L, Rambeaud J-J, Mejean A, Montorsi F,
Bertini R, Patard J-J (2009) A preoperative prognostic model for
patients treated with nephrectomy for renal cell carcinoma. Eur Urol 55:
287–295
Kiehntopf M, Siegmund R, Deufel T (2007) Use of SELDI-TOF mass
spectrometry for identification of new biomarkers: potetential and
limitations. Clin Chem Lab Med 45: 1435–1449
Kiernan UA, Tubbs KA, Nedelkov D, Niederkofler EE, Nelson RW (2003)
Detection of novel truncated forms of human serum amyloid A protein
in human plasma. FEBS Lett 537: 166–170
Kimura M, Tomita Y, Imai T, Saito T, Katagiri A, Ohara-Mikami Y,
Matsudo T, Takahashi K (2001) Significance of serum amyloid a on
the prognosis in patients with renal cell carcinoma. Cancer 92(8):
2072–2075
Komai Y, Saito K, Sakai K, Morimoto S (2007) Increased preoperative
serum C-reactive protein level predicts a poor prognosis in patients with
localized renal cell carcinoma. BJU Int 99: 77–80
Koomen JM, Haura EB, Bepler G, Sutphen R, Remily-Wood ER, Benson K,
Hussein M, Hazlehurst LA, Yeatman TJ, Hildreth LT, Sellers TA,
Jacobsen PB, Fenstermacher DA, Dalton WS (2008) Proteomic contribu-
tions to personalized cancer care. Mol Cell Proteomics 7: 1780–1794
Koomen JM, Li D, Xiao LC, Liu TC, Coombes KR, Abbruzzese J, Kobayashi R
(2005) Direct tandem mass spectrometry reveals limitations in protein
profiling experiments for plasma biomarker discovery. J Proteome Res 4(3):
972–981
Kosari F, Parker AS, Kube DM, Lohse CM, Leibovich BC, Blute ML, Cheville
JC, Vasmatzis G (2005) Clear cell renal carcinoma: gene expression
analyses identify a potential signature for tumour aggressiveness. Clin
Cancer Res 11(14): 5128–5139
Lane BR, Kattan MW (2008) Prognostic models and algorithms in renal cell
carcinoma. Urol Clin North Am 35: 613–625
Liaw A, Weiner M (2002) Classification and regression by randomForest.
Rnews 2: 18–22
Liou LS, Shi T, Duan ZH, Sadhukhan P, Der SD, Novick AA,
Hissong J, Skacel M, Almasan A, DiDonato JA (2004) Microarray
gene expression profiling and analysis in renal cell carcinoma. BMC Urol
4: 9
Malle E, De Beer FC (1996) Human serum amyloid A (SAA) protein:
a prominent acute-phase reactant for clinical practice. Eur J Clin Invest
26: 427–435
Malle E, Sodin-Semrl S, Kovacevic A (2009) Serum amyloid A: an acute
phase protein involved in tumour pathogenesis. Cell Mol Life Sci 66:
9–26
McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM
(2005) Reporting recommendations for tumor marker prognostic studies
(REMARK). J Natl Cancer Inst 97(16): 1180–1184
M u n r oN P ,C a i r n sD A ,C l a r k eP ,R o g e r sM ,S t a n l e yA J ,B a r r e t tJ H ,H a r n d e nP ,
Thompson D, Eardley I, Banks RE, Knowles MA (2006) Urinary
biomarker profiling in transitional cell carcinoma. Int J Cancer 119:
2642–2650
Paret C, Scho ¨n Z, Szponar A, Kovacs G (2010) Inflammatory protein serum
amyloid A1 marks a subset of conventional renal cell carcinomas with
fatal outcome. Eur Urol 859–866
Peng J, Stanley AJ, Cairns D, Selby PJ, Banks RE (2009) Using the protein
chip interface with quadrupole time-of-flight mass spectrometry to
directly identify peaks in SELDI profiles - initial evaluation using low
molecular weight serum peaks. Proteomics 9: 492–498
Raj GV, Thompson RH, Leibovich BC, Blute ML, Russo P, Kattan MW
(2008) Preoperative nomogram predicting 12-year probability of
metastatic renal cancer. J Urol 179: 2146–2151
Ramankulov A, Lein M, Johannsen M, Schrader M, Miller K, Loening SA,
Jung K (2008) Serum amyloid A as indicator of distant metastases but
not as early tumor marker in patients with renal cell carcinoma. Cancer
Lett 269: 85–92
Ramsey S, Lamb GWA, Aitchison M, McMillan DC (2008) Prospective
study of the relationship between the systemic inflammatory response,
prognostic scoring systems and relapse-free and cancer-specific survival
in patients undergoing potentially curative resection for renal cancer.
Br J Urol 101: 959–963
Richter R, Schulz-Knappe P, Schrader M, Standker L, Jurgens M, Tammen
H, Forssmann WG (1999) Composition of the peptide fraction in human
blood plasma: database of circulating human peptides. J Chromatogr B
Biomed Sci Appl 726(1–2): 25–35
Rini BI, Campbell SC, Escudier B (2009) Renal cell carcinoma. Lancet 373:
1119–1132
Rocken C, Menard R, Buhling F, Vockler S, Raynes J, Stix B, Kruger S,
Roessner A, Kahne T (2005) Proteolysis of serum amyloid A and AA
amyloid proteins by cystine proteases: cathepsin B generates AA amyloid
proteins and cathepsin L may prevent their formation. Ann Rheum Dis
64: 808–815
Rogers MA, Clarke P, Noble J, Munro NP, Paul A, Selby PJ, Banks RE (2003)
Proteomic profiling of urinary proteins in renal cancer by surface
enhanced laser desorption ionisation (SELDI) and neural network
analysis: identification of key issues affecting potential clinical utility.
Cancer Res 63(20): 6971–6983
Rouviere O, Bouvier R, Negrier S, Badet L, Lyonnet D (2006) Nonmetastatic
renal-cell carcinoma: is it really possible to define rational guidelines for
post-treatment follow-up? Nat Clin Pract Oncol 3(4): 200–213
Stix B, Kahne T, Sletten K, Raynes J, Roessner A, Rocken C (2001)
Proteolysis of AA amyloid fibril proteins by matrix metalloproteinases-1,
-2, and -3. Am J Pathol 159: 561–570
Tolson J, Bogumil R, Brunst E, Beck H, Elsner R, Humeny A, Kratzin H,
Deeg M, Kuczyk M, Mueller GA, Mueller CA, Flad T (2004) Serum
protein profiling by SELDI mass spectrometry: detection of multiple
variants of serum amyloid alpha in renal cancer patients. Lab Invest
84(7): 845–856
SAA and prognosis in renal cancer
SL Wood et al
110
British Journal of Cancer (2010) 103(1), 101–111 & 2010 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
svan der Hilst JCH, Kluve-Beckerman B, van der Meer JW, Simon A (2009)
Cathepsin D activity protects against development of type AA amyloid
fibrils. Eur J Clin Invest 39: 412–416
Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H,
Olshen AB, Fleisher M, Lilja H, Brogi E, Boyd J, Sanchez-Carbayo M,
Holland EC, Cordon-Cardo C, Scher HI, Tempst P (2006) Differential
exoprotease activities confer tumor-specific serum peptidome patterns.
J Clin Invest 116(1): 271–284
Whelan LC, Power KAR, McDowell DT, Kennedy J, Gallagher WM (2008) Appli-
cations of SELDI-MS technology in oncology. JC e l lM o lM e d12: 1535–1547
Young AC, Craven RA, Cohen D, Taylor C, Booth C, Harnden P, Cairns DA,
Astuti D, Gregory W, Maher ER, Knowles MA, Joyce A, Selby PJ, Banks
RE (2009) Analysis of VHL gene alterations and their relationship to
clinical parameters in sporadic conventional renal cell carcinoma. Clin
Cancer Res 15: 7582–7592
Zhou M, Prieto DA, Lucas DA, Chan KC, Issaq HJ, Veenstra TD, Conrads
TP (2006) Identification of the SELDI ProteinChip human serum
retentate by microcapillary liquid chromatography-tandem mass
spectrometry. J Proteome Res 5: 2207–2216
This work is licensed under the Creative Commons
Attribution-NonCommercial-Share Alike 3.0 Unported
License. To view a copy of this license, visit http://creativecommons.
org/licenses/by-nc-sa/3.0/
SAA and prognosis in renal cancer
SL Wood et al
111
British Journal of Cancer (2010) 103(1), 101–111 & 2010 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s